Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2013 | case report | Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

memo - Magazine of European Medical Oncology > Ausgabe 2/2013
Cathrin Skrabs, Christian Sillaber, Ana-Iris Schiefer, Ingrid Simonitsch-Klupp, Thomas Staudinger, Monique Putman, Werner Rabitsch, Ulrich Jaeger



Patients with follicular lymphoma ineligible for standard treatment with the anti-CD20 antibody rituximab represent a considerable challenge as they require alternative therapeutic approaches.

Patient and methods

We describe a patient who experienced a severe episode of serum sickness. Antichimeric antibodies against rituximab were verified in an early stage of disease, rendering further use of the drug impossible. After five treatment lines he developed progressive follicular lymphoma with skin involvement, which was treated with lenalidomide monotherapy.


Six cycles of lenalidomide monotherapy (25 mg orally for 21 days, 1 week off) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalidomide in follicular lymphoma are reviewed.


As shown here, single-agent lenalidomide represent a therapeutic option for pretreated patients with follicular lymphoma ineligible for rituximab.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013 Zur Ausgabe